Compare Inovio Pharmaceuticals Inc (INO) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Lowe`s Companies Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Lowe`s Companies Inc trades at $203.77 (market cap $114.78B). The key difference: Lowe`s Companies Inc is far larger — about 1285.8× Inovio Pharmaceuticals Inc's market cap, and Lowe`s Companies Inc pays a 2.44% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LOW | |
|---|---|---|
Market Cap | $89.27M | $114.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $287.39 |
52-Week Low | $1.05 | $204.76 |
Enterprise Value | $60.28M | $156.54B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Lowe's Companies (LOW) trades at $203.52, down 2.5% over the past day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $4.26. Revenue declined to $83.67 billion in 2025, but net income margin remains healthy at 7.51%. Analyst consensus is strongly bullish with a $260.88 price target, though technical indicators show selling pressure and support near $196.
LOW presents a mixed outlook: strong fundamentals and analyst support contrast with near-term technical weakness. Upside potential exists if earnings momentum continues and interest rate declines benefit home improvement spending. Key risks include revenue volatility, high debt levels, and competitive pressures. The stock's current dip may offer a buying opportunity for long-term investors, contingent on macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
